GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fuan Pharmaceutical (Group) Co Ltd (SZSE:300194) » Definitions » Beneish M-Score

Fuan Pharmaceutical (Group) Co (SZSE:300194) Beneish M-Score : -2.71 (As of Apr. 09, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Fuan Pharmaceutical (Group) Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.71 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Fuan Pharmaceutical (Group) Co's Beneish M-Score or its related term are showing as below:

SZSE:300194' s Beneish M-Score Range Over the Past 10 Years
Min: -3.33   Med: -2.59   Max: -1.62
Current: -2.71

During the past 13 years, the highest Beneish M-Score of Fuan Pharmaceutical (Group) Co was -1.62. The lowest was -3.33. And the median was -2.59.


Fuan Pharmaceutical (Group) Co Beneish M-Score Historical Data

The historical data trend for Fuan Pharmaceutical (Group) Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fuan Pharmaceutical (Group) Co Beneish M-Score Chart

Fuan Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.15 -2.82 -3.04 -2.45 -2.65

Fuan Pharmaceutical (Group) Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -2.65 -2.60 -2.70 -2.71

Competitive Comparison of Fuan Pharmaceutical (Group) Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Fuan Pharmaceutical (Group) Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuan Pharmaceutical (Group) Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuan Pharmaceutical (Group) Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Fuan Pharmaceutical (Group) Co's Beneish M-Score falls into.


;
;

Fuan Pharmaceutical (Group) Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Fuan Pharmaceutical (Group) Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8252+0.528 * 1.0793+0.404 * 0.9152+0.892 * 1.0149+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8502+4.679 * -0.029855-0.327 * 0.9137
=-2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥371 Mil.
Revenue was 562.27 + 623.613 + 809.4 + 664.766 = ¥2,660 Mil.
Gross Profit was 292.027 + 351.733 + 413.025 + 308.573 = ¥1,365 Mil.
Total Current Assets was ¥2,169 Mil.
Total Assets was ¥6,040 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,765 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥712 Mil.
Total Current Liabilities was ¥1,309 Mil.
Long-Term Debt & Capital Lease Obligation was ¥190 Mil.
Net Income was 85.129 + 93.977 + 122.5 + -19.972 = ¥282 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 53.498 + 92.773 + 154.574 + 161.124 = ¥462 Mil.
Total Receivables was ¥443 Mil.
Revenue was 654.466 + 637.495 + 691.026 + 638.001 = ¥2,621 Mil.
Gross Profit was 350.826 + 351.494 + 402.072 + 347.59 = ¥1,452 Mil.
Total Current Assets was ¥2,109 Mil.
Total Assets was ¥6,165 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,708 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥825 Mil.
Total Current Liabilities was ¥1,137 Mil.
Long-Term Debt & Capital Lease Obligation was ¥538 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(371.385 / 2660.049) / (443.457 / 2620.988)
=0.139616 / 0.169195
=0.8252

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1451.982 / 2620.988) / (1365.358 / 2660.049)
=0.553983 / 0.513283
=1.0793

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2169.46 + 1765.011) / 6040.326) / (1 - (2108.699 + 1708.181) / 6165.437)
=0.348633 / 0.380923
=0.9152

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2660.049 / 2620.988
=1.0149

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1708.181)) / (0 / (0 + 1765.011))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(711.953 / 2660.049) / (825.056 / 2620.988)
=0.267647 / 0.314788
=0.8502

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((190.472 + 1309.414) / 6040.326) / ((538.437 + 1137.154) / 6165.437)
=0.248312 / 0.271772
=0.9137

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(281.634 - 0 - 461.969) / 6040.326
=-0.029855

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Fuan Pharmaceutical (Group) Co has a M-score of -2.71 suggests that the company is unlikely to be a manipulator.


Fuan Pharmaceutical (Group) Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Fuan Pharmaceutical (Group) Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fuan Pharmaceutical (Group) Co Business Description

Traded in Other Exchanges
N/A
Address
No.1 Huanan 1 Road, Changshou District, Chongqing, CHN, 401254
Fuan Pharmaceutical (Group) Co Ltd is mainly engaged in the production and sales of bulk drugs and preparations. The company mainly deals with anti-infective, anti-tumor, mental nervous system, cardiovascular and cerebrovascular, digestive system, endocrine and metabolic, bone and muscle systems. Its products include penicillin and cephalosporins.
Executives
Wu Xiong Hui Executives
Huang Tao Directors, executives
Feng Jing Executives
Yu Xue Song Directors, executives
Hong Rong Chuan Executives
Tang Qin Secretary, Director
Wang Tian Xiang Director
Sun Yong Ping Executives
Jiang Chen Directors, executives
Huang Dao Fei Supervisors
Wen Min Director
Zhou Xu Dong Executives
Zhou Zhong Sheng Supervisors

Fuan Pharmaceutical (Group) Co Headlines

No Headlines